Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLA5PR GLARS-NF1 vs Pregabalin in Peripheral Neuropathic Pain
NCT03221907Phase 3Completed
- Sponsor
- Daewon Pharm
- Start
- Apr 2016
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
A Phase 3 trial of GLA5PR GLARS-NF1 in Peripheral neuropathic pain, sponsored by Daewon Pharm. Started Apr 2016; status: completed.
02
Drugs
GLA5PR GLARS-NF1
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT03221907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221907.